2023 JAMA study reports a 600% increase in US teens/young adults' monthly use of weight-loss drugs Ozempic and Wegovy (GLP-1 receptor agonists)
Use of weight-loss drugs like Ozempic and Wegovy, known as GLP-1 receptor agonists, has surged among US teens and young adults. Monthly use of the medications increased 600% among people aged 12 to 25 between 2020 and 2023, according to a new study published in the Journal of the American Medical Association. The report used dispensing records from nearly 94% of U.S. retail pharmacies.
May 22, 2024
24 Articles